HIV Prevention in OB/GYN Care

Target Audience

This activity is designed for obstetrician/gynecologist (OB/GYN) physicians, nurse practitioners, physician assistants, and nurses who have not yet prescribed preexposure prophylaxis (PrEP) or who are new to PrEP provision.

Program Overview

Many women are at risk for contracting HIV and would benefit from PrEP. OB/GYNs are well placed to evaluate sexual health and discuss and initiate PrEP, yet are often hesitant to discuss PrEP. There are currently 4 available PrEP options: 2 oral options and 2 long-acting injectable (LAI) options. OB/GYNs should be able to discuss nuances of each of the 4 options with their patients and feel comfortable initiating treatment if the patient is interested. In this interactive activity, Dr. Charlotte Rolle discusses strategies for sexual health discussion and assessment of risk factors for HIV, incorporation of trauma-informed approaches, safety and efficacy of PrEP options, administration instructions, and how to assess and support adherence.

Educational Objectives

After completing this activity, the participant should be better able to:

• Demonstrate an understanding of HIV epidemiology among women in the US
• Incorporate nonstigmatizing HIV risk and PrEP eligibility assessments with all sexually active patients in the OB/GYN setting 
• Describe key components of oral PrEP initiation and management for the OB/GYN patient population
• Review protocols for implementing LAI PrEP regimens for the OB/GYN patient population

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Charlotte-Paige Rolle, MD, MPH: Consulting Fees: Gilead Sciences, Inc., Theratechnologies, Inc., ViiV Healthcare; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g. speakers’ bureaus): Gilead Sciences, Inc., ViiV Healthcare Company; Contracted Research: Gilead Sciences, Inc., MSD, ViiV Healthcare Company

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.